diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5424diaendo-5424Research ArticleСтатьиArticlesПрименение дулоксетина - двойного ингибитора обратного захвата в лечении болевой диабетической невропатииUse of dual action inhibitor (duloxetine) in diabetic neuropathyГурьеваИрина ВладимировнаGur'evaIrina Vladimirovna-Федеральное бюро медико-социальной экспертизы, Москва; Российская медицинская академия последипломного образования, Москва200915032009121№1 (2009)5558Copyright © Гурьева И.В., 20092009Гурьева И.В.Gur'eva I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5424

Невропатическая боль при сахарном диабете имеет сложный характер и вызывается в отличие от ноцицептив- ной боли ? нарушениями как в периферической, так и центральной нервной системе. Накапливается все больше данных, свидетель- ствующих о целом спектре нарушений, включая изменения струк- туры и функции спинного мозга, тала мическую нейрональную дисфунк цию, снижение ингибиторного влияния нисходящих невро- нальных путей. Прогресс в изучении патогенеза невропатии открывает новые пути поиска препаратов, оказывающих непо- средственное влияние на патофизиологические механизмы боли. Применение у больных сахарным диабетом дулоксетина (симбал- ты) ? сбалансированного селективного двойного ингибитора обратного захвата серотонина и норадреналина, занимает важное место в комплексном лечении болевой диабетической невропатии

сахарный диабетдиабетическая невропатияхроническая больингибитор двойного действияdiabetes mellitusdiabetic neuropathychronic paindual action inhibitorReferencesZiegler D., Rathmann W.Dickhause T., Meisinger C.,MielckA., KORA Study Group. Prevalence of polyneuropathy in prediabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONIKA/KORA Augsburg Surveys S2 and S3.Diabetes Care 2008; 31: 464-469.Ziegler D., Rathmann W.Dickhause T., Meisinger C.,MielckA., KORA Study Group. Prevalence of polyneuropathy in prediabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONIKA/KORA Augsburg Surveys S2 and S3.Diabetes Care 2008; 31: 464-469.J.Show. P.Z.Zimmet, F.A.Gries and D.Ziegler. Epidemiology of Diabetic Neuropathy. In: Gries FA, Cameron NE, Low PA, Ziegler D (eds) Textbook of diabetic neuropathy. 2003;Thieme, Stuttgart, pp.64-82.J.Show. P.Z.Zimmet, F.A.Gries and D.Ziegler. Epidemiology of Diabetic Neuropathy. In: Gries FA, Cameron NE, Low PA, Ziegler D (eds) Textbook of diabetic neuropathy. 2003;Thieme, Stuttgart, pp.64-82.Tesfaye S, Kempler P. Diabetologia 2005; 48:805-807.Tesfaye S, Kempler P. Diabetologia 2005; 48:805-807.Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatment of neuropathic pain: an update and effect related to mecanosm of drug action. Pain 1999; 83: 389-400.Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatment of neuropathic pain: an update and effect related to mecanosm of drug action. Pain 1999; 83: 389-400.Davies M., Brophy S., Williams R., Taylor A. The prevalence, severity, and impact of painful diabetic neuropathy in type 2 diabetes. Diabetes care 2006: 29; 1580-1522.Davies M., Brophy S., Williams R., Taylor A. The prevalence, severity, and impact of painful diabetic neuropathy in type 2 diabetes. Diabetes care 2006: 29; 1580-1522.Ziegler D. Painful diabetic neuropathy:treatment and future aspects. Diabetes Metab Res Rev 2008:24(supple 1): 52-57.Ziegler D. Painful diabetic neuropathy:treatment and future aspects. Diabetes Metab Res Rev 2008:24(supple 1): 52-57.Breivik H, Collett B., Ventafridda V., Cohen R. and Callacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4): 287-333.Breivik H, Collett B., Ventafridda V., Cohen R. and Callacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4): 287-333.Moshizucki D. Serotonin and noradrenalin reuptake inhibitors in animal models of pain. Hum Psychopharmacol Clin Exp 2004; 19: S15-S19.Moshizucki D. Serotonin and noradrenalin reuptake inhibitors in animal models of pain. Hum Psychopharmacol Clin Exp 2004; 19: S15-S19.Kranzler J.D., Gendreau JR,Rao SG.2002 The psychopharmacology of fybromyalgia: a drug development perspective. Psychopharmacol Bull 36; 165-213.Kranzler J.D., Gendreau JR,Rao SG.2002 The psychopharmacology of fybromyalgia: a drug development perspective. Psychopharmacol Bull 36; 165-213.Fishbain D.2000 Evidence-based data on pain relief with antidepressants. Ann Med 32:305-316.Fishbain D.2000 Evidence-based data on pain relief with antidepressants. Ann Med 32:305-316.Delgado P.L. Common pathways of depression and pain. J Clin Psychiatry 2004;65 (suppl 12):16-20.Delgado P.L. Common pathways of depression and pain. J Clin Psychiatry 2004;65 (suppl 12):16-20.Smith T and Nicholson RA . Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health and Risk Management 2007: 3(6) 833-844.Smith T and Nicholson RA . Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health and Risk Management 2007: 3(6) 833-844.Kapur D.,Neuropathic pain and diabetes. Diabetes Metab Res Rev 2003; 19: 9-15.Kapur D.,Neuropathic pain and diabetes. Diabetes Metab Res Rev 2003; 19: 9-15.Dejong RN. CNS manifestation of diabetes mellitus Postgrad Med 1977; 61: 101-107.Dejong RN. CNS manifestation of diabetes mellitus Postgrad Med 1977; 61: 101-107.Tesfay S, Selvarajah D,Emery CJ et al. Thalamic sensory neuronal dysfunction in distal symmetrical polyneuropathy. Diabetologia 47 (Suppl 1): A365.Tesfay S, Selvarajah D,Emery CJ et al. Thalamic sensory neuronal dysfunction in distal symmetrical polyneuropathy. Diabetologia 47 (Suppl 1): A365.Ziegler D, Ametov A, Barinov A, et al. Oral Treatment With A-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy The SYDNEY 2 trial. Diabetes Care 2006; 29: 2365-70.Ziegler D, Ametov A, Barinov A, et al. Oral Treatment With A-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy The SYDNEY 2 trial. Diabetes Care 2006; 29: 2365-70.Ziegler D. Treatment of neuropathic pain. In: Gries FA, Cameron NE, Low PA, Ziegler D (eds) Textbook of diabetic neuropathy. Thieme, Stutgart, p. 211-224.Ziegler D. Treatment of neuropathic pain. In: Gries FA, Cameron NE, Low PA, Ziegler D (eds) Textbook of diabetic neuropathy. Thieme, Stutgart, p. 211-224.MacFarlane BV, Wright A, O'Callaghan J, Benson HA.1997. Chronic neuropathic pain and its control by drugs. Pharmacology and Theraputics 75, 1-19.MacFarlane BV, Wright A, O'Callaghan J, Benson HA.1997. Chronic neuropathic pain and its control by drugs. Pharmacology and Theraputics 75, 1-19.Yokogawa F, Kiuchi Y, ishikawa Y et al.2002. An investigation of monoamine receptors involved in aminoceptive effects of antidepressants. Anesth Analg 95:163-168.Yokogawa F, Kiuchi Y, ishikawa Y et al.2002. An investigation of monoamine receptors involved in aminoceptive effects of antidepressants. Anesth Analg 95:163-168.Iyengar S, Webster AA, Hemrick-Luecke SK, et al. 2004. Efficacy of Duloxetine, a potent and balanced serotonon-norepinephrine reuptake inhibitor in persistent pain models in rats. J Parm Experim Therap, 311:576-584.Iyengar S, Webster AA, Hemrick-Luecke SK, et al. 2004. Efficacy of Duloxetine, a potent and balanced serotonon-norepinephrine reuptake inhibitor in persistent pain models in rats. J Parm Experim Therap, 311:576-584.Golstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. 2005. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain 116, S. 109-118.Golstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. 2005. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain 116, S. 109-118.Raskin J., Smith T.R., Wong K.et al. 2006 Duloxetine versus routine care in the longterm Management of diabetic peripheral neuropathic pain.J.Palliat Med,9:29-40.Raskin J., Smith T.R., Wong K.et al. 2006 Duloxetine versus routine care in the longterm Management of diabetic peripheral neuropathic pain.J.Palliat Med,9:29-40.Wernicke JF, Pritchett YL, D'SousaDN, et al.2006a A randomized controlled trial of doloxetine in diabetic peripheral neuropathic pain. Neurology, 67: 1411-20.Wernicke JF, Pritchett YL, D'SousaDN, et al.2006a A randomized controlled trial of doloxetine in diabetic peripheral neuropathic pain. Neurology, 67: 1411-20.Wernike J, Lu Y, D'Souza DN, Waninger A, Tran P. Antidepressants: Duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP). In: Abstracts of the 2d Joint scientific meeting of he American pain society. May 2004. J.Pain 2004;5(3 suppl 1), S 48.Wernike J, Lu Y, D'Souza DN, Waninger A, Tran P. Antidepressants: Duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP). In: Abstracts of the 2d Joint scientific meeting of he American pain society. May 2004. J.Pain 2004;5(3 suppl 1), S 48.Duloxetine (Cymbalta) for diabetic neuropathic pain. The medical letter. On drugs and theraputics. Published by the medical letter inc/ NY. Vol.47 (issue 1215|1216), 2005. 67-68.Duloxetine (Cymbalta) for diabetic neuropathic pain. The medical letter. On drugs and theraputics. Published by the medical letter inc/ NY. Vol.47 (issue 1215|1216), 2005. 67-68.Wernicke JF, Raskin J., Rosen A., et al.2006b Duloxetin in long term management of diabetic peripheral neuropathic pain: an open label, 52 week extention of a randomized controlled clinical trial. Curr ther Res Clin Exp, 67;283-304.Wernicke JF, Raskin J., Rosen A., et al.2006b Duloxetin in long term management of diabetic peripheral neuropathic pain: an open label, 52 week extention of a randomized controlled clinical trial. Curr ther Res Clin Exp, 67;283-304.Raskin J, Smith TR, Wong K. et al. Duloxetine versus Routine Care in the long-Term management of diabetic peripheral neuropathic pain, J Palliative Med , Vol.9, No.1 2006, p. 29-40.Raskin J, Smith TR, Wong K. et al. Duloxetine versus Routine Care in the long-Term management of diabetic peripheral neuropathic pain, J Palliative Med , Vol.9, No.1 2006, p. 29-40.Tesfaye S., Chaturvedi N, Eaton SEM, Ward JD, Fuller JH. Cardiovascular risk factors predict the development of diabetic peripheral neuropathy. Diabetes 2000, 49 (Suppl 1): A34.Tesfaye S., Chaturvedi N, Eaton SEM, Ward JD, Fuller JH. Cardiovascular risk factors predict the development of diabetic peripheral neuropathy. Diabetes 2000, 49 (Suppl 1): A34.Smith T.R. Duloxetine in diabetic neuropathy. Expert Opin. Pharmacother. 2006, 7 (2), p. 215-223.Smith T.R. Duloxetine in diabetic neuropathy. Expert Opin. Pharmacother. 2006, 7 (2), p. 215-223.

The authors declare that there are no conflicts of interest present.